지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 43 - 52 (10page)
이용수
초록· 키워드
오류제보하기
Purpose We investigated whether irinotecan plus capecitabine improved progression-free survival (PFS) compared with capecitabine alone in patients with human epidermal growth factor 2 (HER2) negative and anthracycline and taxane pretreated metastatic breast cancer (MBC). Materials and Methods A total of 221 patients were randomly assigned to irinotecan (80 mg/m2, days 1 and 8) and capecitabine (1,000 mg/m2 twice a day, days 1-14) or capecitabine alone (1,250 mg/m2 twice a day, days 1-14) every 3 weeks. The primary endpoint was PFS. Results There was no significant difference in PFS between the combination and monotherapy arm (median, 6.4 months vs. 4.7 months; hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.63 to 1.11; p=0.84). In patients with triple-negative breast cancer (TNBC, n=90), the combination significantly improved PFS (median, 4.7 months vs. 2.5 months; HR, 0.58; 95% CI, 0.37 to 0.91; p=0.02). Objective response rate was numerically higher in the combination arm, though it failed to reach statistical significance (44.4% vs. 33.3%, p=0.30). Overall survival did not differ between arms (median, 20.4 months vs. 24.0 months; p=0.63). While grade 3 or 4 neutropenia was more common in the combination arm (39.6% vs. 9.0%), hand-foot syndrome was more often observed in capecitabine arm. Quality of life measurements in global health status was similar. However, patients in the combination arm showed significantly worse symptom scales especially in nausea/vomiting and diarrhea. Conclusion Irinotecan plus capecitabine did not prove clinically superior to single-agent capecitabine in anthracycline- and taxane-pretreated HER2 negative MBC patients. Toxicity profiles of the two groups differed but were manageable. The role of added irinotecan in patients with TNBC remains to be elucidated.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Cardoso F / 2014 / ESO-ESMO 2nd international consensus guidelines for advanced breast cancer(ABC2)dagger / Ann Oncol 25:1871~1888
Wang JC / 2002 / Cellular roles of DNA topoisomerases : a molecular perspective / Nat Rev Mol Cell Biol 3:430~440
Pizzolato JF / 2003 / The camptothecins / Lancet 361:2235~2242
Ichikawa W / 2004 / Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer / Br J Cancer 91:1245~1250
Guo Y / 2014 / Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer : a meta-analysis / Clin Colorectal Cancer 13:110~118
Wang JC / 2002 / Cellular roles of DNA topoisomerases : a molecular perspective / Nat Rev Mol Cell Biol 3:430~440
Pizzolato JF / 2003 / The camptothecins / Lancet 361:2235~2242
Ichikawa W / 2004 / Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer / Br J Cancer 91:1245~1250
Guo Y / 2014 / Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer : a meta-analysis / Clin Colorectal Cancer 13:110~118
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation
Journal of Gastric Cancer
2023 .04
-
Effect of time interval between capecitabine intake and radiotherapy on local recurrence-free survival in preoperative chemoradiation for locally advanced rectal cancer
Radiation oncology journal : ROJ
2017 .01
-
Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
Cancer Research and Treatment
2015 .01
-
Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
Cancer Research and Treatment
2015 .01
-
Long-term oncologic outcomes of neoadjuvant concurrent chemoradiotherapy with capecitabine and radical surgery in locally advanced rectal cancer : 10-year experiences at a single institution
Annals of Surgical Treatment and Research
2016 .10
-
A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer
Cancer Research and Treatment
2023 .01
-
Changes in the Mean Corpuscular Volume after Capecitabine Treatment are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer
Cancer Research and Treatment
2015 .01
-
Aromatase Inhibition and Capecitabine Combination as 1<sup>st</sup> or 2<sup>nd</sup> Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Additional 4-week capecitabine during the resting periods after 6-week neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer : long-term oncologic outcomes
Annals of Surgical Treatment and Research
2018 .06
-
Nasolacrimal Duct Stenosis after Oral Capecitabine Administration
Korean Journal of Ophthalmology
2019 .01
-
A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
Cancer Research and Treatment
2017 .07
-
Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy
Gut and Liver
2017 .01
-
전이성 유방암 환자의 통합 암 치료에 대한 증례보고
대한암한의학회지
2019 .01
-
A Case of Capecitabine-Induced Discoid Lupus Erythematosus
Annals of Dermatology
2020 .01
-
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
Cancer Research and Treatment
2023 .04
-
Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer
Cancer Research and Treatment
2015 .01
-
Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma
Annals of Dermatology
2019 .01
-
Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis
Cancer Research and Treatment
2018 .01
-
A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer
Cancer Research and Treatment
2022 .04
이 논문의 저자 정보
최근 본 자료
댓글(0)
0